Summit Therapeutics Inc. (SMMT)
NASDAQ (NMS) NASDAQ (NMS) Primary 
XMEX 
Summit to Divest Late-Stage Antibiotic Drug to Biossil in $105M Deal
SMMT divests investigational antibiotic ridinilazole to Biossil for upfront cash, milestone payments and royalties as it sharpens its focus on oncology.
Summit Therapeutics: High-Volatility, Catalyst-Driven Binary Bet
Summit Therapeutics is a highly volatile, single-asset company with a binary outcome. SMMT exhibits unusually concentrated ownership and heightened short interest, creating conditions for a short squeeze to take place. Recent pullbacks, driven by mixed market receptions to events do not fundamentally alter the investment narratives, present investors with an attractive entry point ahead of key catalysts.
Summit Therapeutics Inc. (SMMT) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Summit Therapeutics Inc. (SMMT) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
All You Need to Know About Summit Therapeutics (SMMT) Rating Upgrade to Buy
Summit Therapeutics (SMMT) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Wall Street Analysts Think Summit Therapeutics (SMMT) Could Surge 67.1%: Read This Before Placing a Bet
The consensus price target hints at a 67.1% upside potential for Summit Therapeutics (SMMT). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
A hotly debated lung cancer drug cut the risk of death by 34% in a late-stage trial in China
An experimental lung cancer drug from Akeso and Summit Therapeutics improved survival in the Harmoni-6 Phase 3 trial conducted in China, according to results being presented at the American Society of Clinical Oncology annual meeting. Called ivonescimab, the bispecific antibody targets PD-1 — similar to Merck's best-selling drug Keytruda — and VEGF — similar to Roche's Avastin.
SMMT Q1 Loss Narrower Than Expected, Stock Down on Ivonescimab Setback
Summit Therapeutics posts narrower Q1 loss but stock plunges 25% after ivonescimab setback, raising concerns over its late-stage cancer pipeline progress.
SMMT Stock Up 24% in Three Months: Here's What You Need to Know
Summit Therapeutics stock jumps as FDA accepts ivonescimab BLA. Strong trial data and partnerships boost confidence in its cancer therapy pipeline.
Summit Therapeutics Inc. (SMMT) Presents at The Citizens Life Sciences Conference 2026 Transcript
Summit Therapeutics Inc. (SMMT) Presents at The Citizens Life Sciences Conference 2026 Transcript
SMMT Incurs Wider-Than-Expected Q4 Loss, Pipeline Progress in Focus
Summit Therapeutics posts a wider Q4 loss as R&D spending surges. Its ivonescimab pipeline advances with a BLA filing and multiple late-stage cancer trials underway.
Summit Therapeutics Inc. (SMMT) Q4 2025 Earnings Call Transcript
Summit Therapeutics Inc. (SMMT) Q4 2025 Earnings Call Transcript
FDA Accepts SMMT's Application Seeking Approval for NSCLC Drug
Summit Therapeutics' ivonescimab BLA wins FDA acceptance for EGFR-mutated NSCLC, with a PDUFA action date of Nov. 14, 2026.
